Ed Miseta - Chief Editor, Clinical Leader & Outsourced Pharma

Ed Miseta

Ed Miseta



Ed Miseta is chief editor for the website Clinical Leader, executive editor for Life Science Leader magazine, conference chair for Clinical Leader Forum, and host of Clinical Leader Live. Ed studied Business Economics at The Pennsylvania State University and also holds a Master’s degree in Business Administration. Ed has been a writer for more than 12 years and has been covering clinical research since January 2013. Ed spent 10 years in banking and investments and also taught economics at Penn State for 8 years. In his current position, Ed interviews clinical executives from pharmaceutical and biotech companies and shares their insights with readers. His primary focus is on best practices, challenges faced and overcome, clinical trends, partnering, and implementing new technologies. He has also moderated numerous speaker panels at industry conferences and trade shows.

ED'S WORK

Arrow Target
Janssen’s Innovation Strategy To Target Immune-Mediated Disease
Tom Cavanaugh believes there is a tremendous unmet need in the industry for treatments that target patients suffering from immune-mediated diseases. Cavanaugh, the president of immunology for Janssen in the U.S., notes that unmet need is a primary factor that drives the work he and his team perform.   Continue Reading..
Elpis_450x300.jpg
From Medical Researcher To CEO
Yan Chen used her industry experience and interest in immunology to start Elpis Biopharmaceuticals, a company hoping to find cures for difficult-to-treat cancers.  Continue Reading..
Dollar Signs
Research Report Shows Phase II/III Spending Will Increase
Research firm Industry Standard Research recently published its Phase II/III Study Trends and Market Outlook report. The goal of this report is to provide readers with a high-level view of the Phase II/III clinical development space to illustrate current market dynamics and inform strategic planning.   Continue Reading..
Clinical trials outlook bucket 450x300.jpg
AI And Machine Learning Prepare Pharma For The Data Onslaught
When I reached out to several clinical executives in my network for their thoughts on trends that will impact trials in the coming year, the two mentioned most frequently were AI and decentralized trials.  Continue Reading..
Morphogenesis_450x300.jpg
Pets, Perseverance, And Manufacturing Facility Bring Biotech Success
Patricia Lawman, cofounder and CEO of the biotech firm Morphogenesis, explains the company’s unlikely genesis and different approach to animal testing.  Continue Reading..
Felxion_450x300.jpg
How Flexion Pivoted To Become A Commercial Biotech
Unfortunately, Flexion’s incorporation coincided with the financial crisis of 2007-2008, and the assumption that large pharma’s would pay premiums for successful proof of concept assets came under pressure.  Continue Reading..
Lilly_Lotus Mallbris_450x300.jpg
The Benefits & Challenges Of Head-To-Head Trials
In Lilly’s immunology portfolio, eight different H2H clinical trials have been conducted thus far. Four of those trials were conducted in parallel with a Phase 3 trial and four were conducted after it. Although the benefits are attractive to a sponsor company, H2H trials can present some unique risks.  Continue Reading..
Aerami Therapeutics_Anne Whitaker_450x300.jpg
A Quick Transition From Research Firm To Clinical-Phase Biotech
Since Oct. 2018, Anne Whitaker had to figure out how to transition Aerami Therapeutics from a research firm to a clinical-phase company. It’s been a complicated and challenging journey.  Continue Reading..
01_FromThe CRO 0517_450by300
DIA And CRO Leadership Awards Go Virtual
The team behind DIA’s Annual Meeting was able to put together an event that was as informative and engaging as past years, despite the short and very hectic time frame. More than 200 sessions took place virtually, with 120 of those being on demand.  Continue Reading..
Paratek_450x300.jpg
Why Is Antibiotic Development In The U.S. Disappearing?
Today, 95 percent of antibiotics in development are being studied by smaller biotechs, including Paratek Pharmaceuticals. Today, the company is on a strong trajectory, but its ups and downs show why antibiotic companies fail and few new antibiotics reach patients.  Continue Reading..